Inquired if Q1 re-verification issues impacted Q2, why guidance was trimmed despite strong Q2, and the discrepancy between company reports and IQVIA data.

Confirmed Q1 re-verification issues are behind them with no Q2 impact. Stated Q2 performance was within guidance, and the guidance revision accounts for H1 results while H2 expectations remain intact. Dismissed IQVIA data as volatile and not always reflective of actual revenues, emphasizing internal metrics provided. “First is on the insurance re-verification, which impacted the performance in the first quarter. That issue is behind us and there's no impact from insurance re-verifications in the Q2 number.”

Asked what factors led to the guidance revision despite meeting Q1/Q2 internal guidance, and what gives confidence in the significant Q4 step-up given last year's slower Q4.

Explained guidance revision primarily reflects H1 actuals, with H2 expectations largely intact. Reaffirmed strong momentum in existing specialties (record July cases) and positive early gout expansion metrics. Stated no additional headwinds are anticipated. Attributed Q4 confidence to the full impact of the 3x larger gout sales force expansion, which was operational by end of June. “So the revised guidance is simply taking into account the actual results from the first half. And then you asked about the question on the step up in Q4. I think the big difference with last year is, we have an expansion that's 3x the previous year's expansion, right? That's fully operational at the end of June.”

Clarified if "cases" mean prescriptions, asked about script fulfillment lags, and discussed operating leverage beyond 2026.

Confirmed "new cases initiated" are equivalent to prescriptions or enrollment forms. Stated fulfillment time varies but no new lags or headwinds are observed, with processes continually improved. Anticipated significant operating leverage in 2027 from the 2026 sales force expansion, expecting higher sales without further expansion for gout. “So when we say new cases initiated, we mean prescriptions, we mean the same thing as enrollments, enrollment forms.”

ANIP

ANI Pharmaceuticals (ANIP) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 7, 2026

Source: earnings call transcript

Executive summary

ANI Pharmaceuticals Q2 FY26 — Record Revenues and Strong Cortrophin Growth

ANI Pharmaceuticals delivered a strong second quarter, marked by record revenues and EBITDA, driven by robust performance in its rare disease and generics segments. The company is actively transforming into a leading rare disease player, notably through a significant sales force expansion for Cortrophin Gel in the gout market, which is showing promising early indicators. While full-year Cortrophin guidance was modestly adjusted for first-half performance, the company remains confident in its strategic priorities and expects continued growth and operational leverage in 2027.

Highlights

Record Q2 2026 total revenues of $266 million, up 26% year-over-year.
Record Cortrophin Gel net revenues of $117.1 million, up 43% year-over-year and 56% quarter-over-quarter.
Record adjusted EBITDA of $71.6 million, up 32% year-over-year.
Gout expansion sales force fully operational by end of June, with >95% of new reps generating multiple new cases and >1/3 of prescribers initiating 2+ cases.
Full-year 2026 total net revenue guidance reaffirmed at $1.08 billion to $1.14 billion, representing 26% year-over-year growth at midpoint.

Concerns

Cortrophin Gel revenue guidance modestly revised down to $520 million to $540 million (from prior higher expectation) primarily due to H1 2026 results.
Non-GAAP gross margin decreased by approximately 230 basis points year-over-year to 62.6% due to product mix.
ILUVIEN net revenues decreased 16% year-over-year to $18.7 million due to timing of international shipments.

Guidance & targets

Category	Target	Timeline	Confidence
Cortrophin Gel Net Revenue	$520 million to $540 million high materiality	Full-year 2026 · FY26	High
Cortrophin Gel Net Revenue	$143 million to $153 million medium materiality	Q3 · FY26	High
Total Company Net Revenue	$1.08 billion to $1.14 billion high materiality	Full-year 2026 · FY26	High
Total Company Net Revenue	modestly higher as compared to second quarter medium materiality	Q3 · FY26	Medium
Adjusted non-GAAP EBITDA	$285 million to $300 million high materiality	Full-year 2026 · FY26	High
Adjusted non-GAAP EBITDA	down sequentially, however higher than the first quarter of 2026 non-GAAP EBITDA medium materiality	Q3 · FY26	Medium
Adjusted non-GAAP Earnings Per Share	$9.19 and $9.69 high materiality	Full-year 2026 · FY26	High
ILUVIEN Net Revenue	$78 million to $83 million medium materiality	Full-year 2026 · FY26	High
Adjusted Gross Margin	between 59.9% and 60.9% medium materiality	Full-year 2026 · FY26	High
Shares Outstanding for non-GAAP diluted EPS	between 21.5 million and 21.8 million low materiality	Full-year 2026 · FY26	High
U.S. GAAP Effective Tax Rate	approximately 26% to 28% low materiality	Full-year 2026 · FY26	High
Harmony Biosciences Development Milestone Revenue	$2 million low materiality	Q3 · FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Rare Disease - Cortrophin Gel Strong growth driven by existing specialties (rheumatology, nephrology, neurology, ophthalmology, pulmonology). Gout expansion showing strong early demand indicators. Sales force expansion: 50% increase to ~180 repsGout expansion operational: End of JuneNew cases initiated (July): Highest month for existing specialtiesNew sales reps generating multiple new cases (gout): >95%Prescribers initiating 2+ new cases (gout): >1/3Compounded annual growth rate (2022-2025): 103%2025 sales: $348 million	$117.1 million	43%	56%	—
Rare Disease - ILUVIEN Revenue decline due to timing of international shipments. Full-year guidance remains on track. Top-line results from SYNCHRONICITY trial reported, detailed results expected Q4 2026.	$18.7 million	-16%	—	—
Generics Growth driven by partner generic launch, new product introductions, and operational outperformance. Strong R&D capabilities. New product launches (2026 YTD): 12New product launches (2026 full year target): At least 15CGT filings position: #2 playerRevenue from US-manufactured finished goods: ~95%	$99.1 million	10%	—	—
Harmony Biosciences IP Out-licensing Revenue recognized from a licensing transaction entered in January. Remaining $2 million development milestone expected in Q3 2026. Royalty income on WAKIX sales: $9.7 millionDevelopment milestone revenue: $8 million	$17.7 million	—	—	—

Deals & partnerships

Harmony Biosciences Licensing transaction for intellectual property

Entered into in January 2026. Recognized revenue based on royalty income on sales of WAKIX and work completed toward development milestones.

Risks & headwinds

Product mix shift Q2 FY26

Decreased non-GAAP gross margin by approximately 230 basis points year-over-year to 62.6%.

Timing of international shipments for ILUVIEN Q2 FY26

ILUVIEN net revenues down 16% year-over-year to $18.7 million in Q2 FY26.

Mitigation:Company remains on track to meet full-year guidance for ILUVIEN, reflecting stronger revenue in the back half of the year.

Sequential decline in Q3 non-GAAP EBITDA Q3 FY26

Expected to be down sequentially from Q2 FY26 ($71.6M).

Mitigation:Driven by lower Harmony milestone recognition ($2M vs $8M in Q2) and full operating expense of gout expansion; expected to achieve leverage on gout expansion with increasing Cortrophin Gel revenues later.

What to watch in Q3 FY26

Cortrophin Gout Expansion Revenue Contribution

Q3 FY26 and Q4 FY26

Current Limited impact in Q2 FY26; strong early demand indicators (95% reps with multiple new cases, 1/3 prescribers with 2+ cases).

Target Measurable revenues in Q3 FY26, robust growth in Q4 FY26.

Why it matters

The success of the gout expansion is key to Cortrophin's multi-year growth trajectory and the company's transformation into a rare disease leader.

As expected and as previously discussed, given the timing of operationalizing our gout expansion, it did not have a meaningful impact on Q2 reported revenues, but we continue to expect measurable revenues in the third quarter and robust growth in the fourth quarter...

Find out whether ANIP delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked for more detail on gout uptake, confidence in Q4 step-up, and penetration levels in existing Cortrophin indications.

Management highlighted positive leading indicators for gout expansion (95% reps with multiple new cases, 1/3 prescribers with 2+ cases, balanced demand). Explained Q4 step-up due to full impact of 3x larger sales force expansion compared to prior year, continued momentum in existing specialties (record July cases), and typical channel/insurance tailwinds. Stated overall market penetration is "very, very low" with huge opportunity.

“So when you think about the gout expansion, right, we've executed our largest rare disease sales force expansion and we've increased our reps by 50%. This expansion from 120 to 180 reps, right? So that's a meaningful expansion. That expansion was operational by the end of June. I already spoke about the leading indicators of demand. So we expect Q3 to keep building on this momentum and therefore Q4 will have significantly higher impact from the gout expansion.”

asked by Vamil Divan · answered by Nikhil Lalwani

2 min read 6 chapters

Detailed narrative

Transformation to Rare Disease Company

ANI is actively transforming into a leading rare disease company, with rare disease products expected to approach 60% of total revenues in 2026. This strategic shift is supported by the strong performance of Cortrophin Gel and ongoing investments in commercial expansion and potential inorganic growth opportunities. The company aims to create operational leverage in 2027 and beyond from these investments.

Cortrophin Gel Growth and Gout Expansion

Cortrophin Gel revenues grew 43% year-over-year and 56% quarter-over-quarter in Q2 FY26, driven by existing specialties. The company completed its largest rare disease sales force expansion, increasing reps by 50% to approximately 180, specifically targeting acute gouty arthritis flares in podiatry and primary care settings.

Early indicators for the gout expansion are positive, with strong demand generation and high engagement from new sales representatives and prescribers.

Generics Business Performance

The generics business delivered $99.1 million in revenue, up 10% year-over-year, driven by a partner generic launch, new product introductions, and operational execution. ANI launched 12 generics in 2026 and is on track for at least 15 for the full year, maintaining its position as the #2 player in CGT filings. Approximately 95% of generics revenues come from US-manufactured finished goods.

ILUVIEN and Retina Franchise

ILUVIEN generated $18.7 million in Q2 revenue. The company reported top-line results from the Phase 4 SYNCHRONICITY trial in non-infectious uveitis of the posterior segment (NIU-PS) and plans to unveil detailed results at a medical conference in Q4 2026. Management believes the addressable patient populations in DME and NIU-PS represent at least 10x the number of patients currently treated, indicating significant long-term opportunity.

Capital Allocation Strategy

ANI is focused on disciplined capital allocation, prioritizing organic growth investments like the Cortrophin commercial expansion and deploying a high single-digit percentage of generics revenue into R&D. The company is also evaluating inorganic growth opportunities for its rare disease business, seeking commercial or near-commercial assets synergistic with existing call points or infrastructure.

Market Penetration and Growth Runway

The overall ACTH market is healthy, expected to grow nearly 30% to over $1.3 billion in 2026. Cortrophin Gel is expected to grow 50-55% within this market. Management estimates almost 1 million addressable patients across Cortrophin indications, with current ACTH therapies being vastly underpenetrated, suggesting a significant multi-year growth runway.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.